Results 191 to 200 of about 13,782 (258)

Tumor‐Specific Delivery of CD28 siRNA via Lyso‐PC C‐16 Modified Lipid Nanoparticles Overcomes Anti‐PD‐1 Resistance by Remodeling Tumor Microenvironment

open access: yesAdvanced Science, EarlyView.
This study develops 16:0 LPC‐modified lipid nanoparticles (LPC‐LNPs) with cancer cell specificity by exploiting altered tumor lipid metabolism. LPC‐LNPs encapsulating Cd28 small interfering RNA (LPC‐LNP‐Cd28) knock down cancer cell CD28 without affecting T cells, inflame the tumor microenvironment, and overcome anti‐PD‐1 resistance.
Yangyang Chai   +12 more
wiley   +1 more source

Generation of Self‐Organizing Macrovascular Constructs by Bioprinting Human iPSC‐Derived Mesodermal Progenitor Cells

open access: yesAdvanced Science, EarlyView.
ABSTRACT Vascularization remains a major obstacle in tissue engineering. Here, we introduce a bioprinting strategy to generate centimeter‐scale, self‐organizing “mother vessel” constructs from iPSC‐derived hiMPCs. By optimizing bioink composition, printing was accomplished in a single‐step approach. Within one week, hiMPCs differentiated into both CD31+
Leyla E. Dogan   +5 more
wiley   +1 more source

A corona-like distribution and patchy pattern of cerebellar infarcts identify patients with giant cell arteritis. [PDF]

open access: yesTher Adv Neurol Disord
Beuker C   +18 more
europepmc   +1 more source

Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor

open access: yesAdvanced Science, EarlyView.
The study characterizes C36, a highly selective EZH2/PRC2 inhibitor that acts via a novel allosteric mechanism. Unlike previous inhibitors, C36 inhibits EZH2/PRC2 by disrupting the allosteric communication between EZH2 and EED in a SAM‐noncompetitive manner.
Ting Cao   +11 more
wiley   +1 more source

Reciprocal association between neurovascular conflict and trigeminal neuralgia: a systematic review and meta-analysis. [PDF]

open access: yesJ Oral Facial Pain Headache
Golubevas R   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy